|
WO2021072049A1
|
|
High frequency targeted animal transgenesis
|
|
US2021079387A1
|
|
Cleavage-resistant donor nucleic acids and methods of use
|
|
US2021062250A1
|
|
Extrachromosomal dna labeling
|
|
WO2021034585A1
|
|
Live cell imaging of non-repetitive genomic loci
|
|
WO2021016131A1
|
|
Convolutional neural networks for classification of cancer histological images
|
|
WO2020223309A1
|
|
Extrachromosomal dna identification and methods of use
|
|
WO2020168029A1
|
|
Transgenic mouse models supporting innate immune function
|
|
US2020154683A1
|
|
Trpc3 as a therapeutic target for alzheimer's disease
|
|
WO2020092860A1
|
|
Gastric cancer treatments
|
|
WO2020092862A1
|
|
Dlgap2 as a therapeutic target for and alzheimer's disease and age-related cognitive decline
|
|
WO2020092220A1
|
|
Three dimensional human brain tumor models
|
|
WO2020086954A2
|
|
Treatments for charcot-marie-tooth disease
|
|
WO2020086433A1
|
|
Methods and apparatus for phenotype-driven clinical genomics using a likelihood ratio paradigm
|
|
US2020110073A1
|
|
Renal disease targets
|
|
WO2020069331A1
|
|
Artificial rna-guided splicing factors
|
|
WO2020056302A1
|
|
Method and apparatus for detecting copy number variations in a genome
|
|
WO2020041172A1
|
|
Methods and compositions for recruiting dna repair proteins
|
|
WO2020041174A1
|
|
Method of determining toxicity of an immunomodulatory drug
|
|
WO2020037255A1
|
|
Automatic identification and analysis of a tissue sample
|
|
WO2020006394A1
|
|
Breast cancer splice variants
|
